In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|January 26, 2018
Novel Laboratory Automation Platform at SLAS 2018
Author(s)BioPharm International Editors
Formulatrix's Rover Laboratory Automation Platform to support sample preparation will be featured at booth #1335 during the SLAS conference in San Diego, CA, on Feb. 5-8, 2018.
Advertisement
Formulatrix will feature its Rover Laboratory Automation Platform to support sample preparation during the SLAS 2018 conference in San Diego, CA, on Feb. 5–8, 2018, the company announced on Jan. 22, 2018.
The platform will use machine vision and mobile microplate “rovers” that carry microplates around the lab from instrument to instrument, providing researchers with scalability, according to the company. Automated sensors in various pipetting stations, starting with an eight-channel variable spacing air displacement model, will automatically sense liquid levels, liquid classes, and labware geometries.
“The idea behind a results-oriented software interface is that you indicate how you would like your samples to be processed, and the instrument decides how to best perform the liquid handling tasks, sensing liquid levels, viscosities, and labware geometries along the way to ensure highly reproducible sample preparation,” explained Thomas Rawlins, marketing manager at Formulatrix, in a company press release.
When configured with the Mantis Liquid Handler, a microfluidic reagent dispenser with a 6-µL dead volume, and the Constellation digital polymerase chain reaction (PCR) system, a plate-based digital PCR system, the pipetting platform will be released in July 2018 and provide researchers with a full workflow solution for sample preparation and analysis in miniaturized nucleic acid quantification workflows, as stated by the company.
The concept will be featured at booth #1335 of the SLAS 2018 conference during the Solution Spotlight presentation on Monday, Feb. 5, 2018 at 3:30 PM in the Exhibition Theater.
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5